Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the investigational drug SPY072 in adults aged 18 to 75 with moderate to severe hidradenitis suppurativa HS who are also receiving advanced standard of care treatment. This Phase 2, multicenter, randomized, double-blind study aims to assess whether SPY072 can improve symptoms of HS compared to placebo while continuing standard treatment. The study will also monitor safety and how long any treatment effects last. Participants will be randomly assigned to receive either SPY072 or a matching placebo, both given as subcutaneous injections, alongside bimekizumab, an advanced standard of care medication. The treatment period lasts 16 weeks, after which participants enter a follow-up phase to evaluate ongoing safety and durability of response. During the study, participants will undergo regular assessments including clinical evaluations of HS lesions and response to treatment. Researchers will measure outcomes such as the percentage of participants achieving a significant clinical response at Week 16. Safety monitoring will continue up to 52 weeks, and participants progress will be closely tracked throughout the treatment and follow-up periods, which may last until the study ends in mid-2028.
Actively Recruiting
Researchers are evaluating the efficacy and safety of THB335 in adults with chronic spontaneous urticaria CSU who continue to experience hives and itching despite treatment with a second-generation H1 antihistamine. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare two doses of THB335 against a placebo. The study is designed for adults aged 18 to 85 who remain symptomatic despite standard care. Participants will be randomly assigned to receive either a higher dose or a lower dose of THB335, or a matching placebo, taken orally once daily for 12 weeks. All participants will continue their stable antihistamine treatment during this period. The study includes a Screening Period of up to 4 weeks before treatment, followed by a 12-week Treatment Period, and then a 4-week Follow-Up Period. During the trial, participants will complete daily electronic diaries to track symptoms such as hives and itching, and attend scheduled study visits for assessments. Researchers will measure changes in weekly Urticaria Activity Score UAS7 and other related scores from baseline to Week 12. Safety will be monitored through the recording of adverse events, vital signs, and laboratory tests up to Week 16. Overall, the total participation time is approximately 20 weeks.
Actively Recruiting
Healthy Volunteer
Researchers are studying the immune response and safety of two mRNA COVID-19 vaccines, mRNA-1283 and mRNA-1273, which contain variant formulations. This phase 4, open-label trial aims to evaluate these vaccines within the current environment of COVID-19, focusing on how well they stimulate neutralizing antibodies against matched variants. Participants will be randomly assigned to receive a single intramuscular injection of either mRNA-1273 or mRNA-1283 on Day 1. Both vaccines are sterile liquids given as one dose. The study measures immune responses and safety outcomes up to Day 29 following vaccination. During the study, participants will have their antibody levels measured on Day 29 to assess the vaccines immune response. Safety will be monitored throughout the study, including recording any adverse events or serious side effects from Day 1 through the end of the study. The total duration from enrollment to last assessment is approximately 29 days.
Actively Recruiting
Researchers are evaluating AXS-14 esreboxetine for managing fibromyalgia in a Phase 3, double-blind, placebo-controlled, randomized withdrawal study. The study aims to assess the efficacy and safety of AXS-14 for people diagnosed with fibromyalgia based on the 2016 ACR diagnostic criteria. The trial includes a multi-center design with two main periods. First, participants receive open-label AXS-14 tablets once daily for up to 12 weeks. Those who respond to treatment are then randomized to either continue AXS-14 or switch to placebo for an additional 12 weeks or until loss of therapeutic response occurs. Participants will be involved for up to 24 weeks in total. During this time, they will take study tablets daily and undergo assessments to monitor their response and safety. The primary outcome measured is the time from randomization to loss of therapeutic response over 12 weeks. Safety and efficacy are closely monitored throughout the study.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.
Actively Recruiting
Researchers are evaluating how rifaximin 200 mg is processed in the bodies of children aged 6 to 11 years who have acute diarrhea possibly caused by bacteria. The study also aims to assess the safety and effectiveness of rifaximin combined with oral rehydration therapy ORT compared to ORT alone in this pediatric group. This is a phase 4, randomized, open-label trial focusing on treatment outcomes and pharmacokinetics. Participants will be randomly assigned to receive either rifaximin 200 mg tablets three times daily for 3 days combined with ORT or ORT alone according to standard care. The rifaximin group will have blood samples collected on Day 1 and Day 3 to measure drug levels at specific times. All participants will receive ORT as per investigators standard of care and will keep a diary tracking stool frequency, consistency, and symptoms. Participants will attend up to 4 clinic visits during a 5-day treatment period, including screening, Day 1, Day 3 end of treatment, and Day 5 last clinic visit. They will also receive two follow-up phone calls for safety monitoring up to Day 30. Assessments include stool samples to identify bacterial pathogens, blood tests for pharmacokinetics, monitoring for side effects, vital signs, and laboratory tests. The main outcomes measured include rifaximin plasma levels and the proportion of participants achieving clinical cure by Day 5.
Actively Recruiting
Researchers are observing individuals aged 65 years or older who have undergone hereditary cancer genomic testing to understand how this testing can help assess genetic cancer risk and guide doctors in preventive care. The study focuses on hereditary cancer diagnostics to potentially enable early detection and treatment. It collects data related to patients medical history, demographics, physician recommendations, and genetic test results for certain genes linked to hereditary cancer risks. The study does not involve new treatments but collects data from patients who have already had hereditary cancer genomic tests ordered by their physicians for medical reasons. The genes tested may vary over time as new knowledge emerges. Data collection occurs retrospectively over a period of up to 150 days, primarily through one survey form, capturing information related to genetic tests and physician treatment recommendations. Participants provide consent for their data to be included, and the study records information such as medical history, demographic details, and physician specialty. Researchers analyze these data to evaluate the clinical utility of genetic testing for cancer prevention and early detection. An interim analysis will help determine if the number of participants or data collection duration should be adjusted. The overall observation period spans approximately 120 days.
Actively Recruiting
Researchers are evaluating the safety, effectiveness, and immune response of an Acne mRNA vaccine in adults aged 18 to 45 years with moderate to severe acne. This Phase III study is the first to test this vaccine in humans and aims to find the best dose to use in future larger trials. Acne is a common inflammatory skin condition that affects millions worldwide, and current treatments have not changed much over the past 30 years. This study is sponsored by Sanofi Pasteur, a Sanofi Company. The trial includes up to three intramuscular injections of the Acne mRNA vaccine at different dose levels. Participants are divided into four groups two groups receive two injections and two groups receive three injections. Each vaccination group has a matching placebo group for comparison. The Core Study includes Sentinel and Main cohorts for both the two- and three-dose regimens. After completing the Core Study, some participants will enter a long-term follow-up period lasting up to 30 months to assess lasting effects of the vaccine. One group will be invited to join a separate long-term extension study. During the study, participants will be closely monitored for side effects shortly after each injection and for several months thereafter. Researchers will measure changes in the number of acne lesions and immune responses through blood tests. Safety assessments include tracking any adverse events and laboratory test results. Visits will include medical evaluations and questionnaires. The total participation time may extend beyond the Core Study to include long-term follow-up for some participants, lasting up to 38 to 40 months after the first injection.
1-10 of 11
1